Talaporfin
From Self-sufficiency
File:Talaporfin.png | |
Systematic (IUPAC) name | |
---|---|
N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid | |
Clinical data | |
Routes of administration | IV |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
110230-98-3 220201-34-3 (sodium salt) |
ATC code | none |
PubChem | CID 5486799 |
Chemical data | |
Formula | C38H41N5O9 |
Molar mass | 711.76 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664nm normally provided by a laser tuned to this wavelength.[1]
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ http://journals.lww.com/jto/Fulltext/2006/06000/Photodynamic_Therapy__PDT__for_Lung_Cancers.18.aspx "Photodynamic Therapy (PDT) for Lung Cancers" 2006
- ↑ http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer" 2006
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Chemotherapeutic agents
- Photosensitizing agents
- Tetrapyrroles
- Antineoplastic and immunomodulating drug stubs